EGFR and cancer: Several studies have shown that, in addition to delivering the classic proliferation and survival signals, activated EGFR also facilitates glucose utility and metabolic pathways through the stabilization of glucose transporters and dysregulation of glycolytic enzymes hexokinases and pyruvate kinase M2 (PKM2) that promote tumor growth, epithelial-mesenchymal transition (EMT), cancer stemness, and even immune evasion [13–17].